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Abstract
Mutations in FARS2, the gene encoding the mitochondrial phenylalanine-tRNA
synthetase (mtPheRS), have been linked to a range of phenotypes including
epileptic encephalopathy, developmental delay, and motor dysfunction. We
report a 9-year-old boy with novel compound heterozygous variants of FARS2,
presenting with a pure spastic paraplegia syndrome associated with bilateral signal abnormalities in the dentate nuclei. Exome sequencing identified a paternal
nonsense variant (Q216X) lacking the catalytic core and anticodon-binding
regions, and a maternal missense variant (P136H) possessing partial enzymatic
activity. This case confirms and expands the phenotype related to FARS2 mutations with regards to clinical presentation and neuroimaging findings.
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Introduction
Mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs)
play an integral role in mitochondrial protein synthesis
and translation by charging transfer RNAs (tRNA) with
their associated amino acids. To date, most mt-aaRSs
mutations involve a wide spectrum of central nervous system disorders with a broad range of phenotypes.1 For
example, mutations in GARS cause peripheral neuropathy,
MARS2 mutations have been associated with spastic
ataxia with leukoencephalopathy, and DARS2 variants
1128

have been implicated in leukoencephalopathy with
brainstem and spinal cord involvement and lactate
elevation.1–4
FARS2 is a nuclear gene encoding the mitochondrial
phenylalanyl-tRNA synthetase (mtPheRS; MIM#611592),
which transfers phenylalanine to its specific mitochondrial
tRNAPhe. mtPheRS contains four major domains: a mitochondrial localization signal (residues 1–37) in the Nterminal region (residues 1–83), a catalytic domain (residues 84–325), a linker region (residues 326–358), and an
anticodon-binding domain (359–451).5 Similar to many
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mt-aaRSs, FARS2 has been linked with a severe mitochondrial syndrome associated with an infantile-onset
epileptic encephalopathy and/or fatal Alpers-like syndrome.5–9 More moderate phenotypes consisting of cognitive disability, motor delays, and epilepsy have also been
reported.10,11 In its mildest form, FARS2 presented with a
pure spastic paraplegia syndrome in a consanguineous
Chinese family with homozygous mutations (spastic paraplegia type 77; SPG77 MIM#617046).12
We report a 9-year-old boy with progressive lower
extremity spasticity and normal cognition associated with
bilateral signal abnormalities in the dentate nuclei. Exome
sequencing revealed novel compound heterozygous FARS2
mutations: a paternal nonsense variant upstream of the
catalytic core and anticodon-binding region (c.646 C>T;
p.Q216X) and a maternal missense variant (c.407 C>A;
p.P136H) associated with decreased enzyme activity. This
combination of alleles with null and partial activity
resulted in this unique case of SPG77.

Material and Methods
A detailed description of materials and methods used can
be found in the Data S1.

Results
Subject
The subject was a 9-year-old boy, born to healthy nonconsanguineous parents. His parents were of northern
European and Ashkenazi Jewish ancestry and were without neurological issues. Family history was negative. His
early development was normal. He started walking at
14 months and was speaking in sentences by age 2. At
approximately 2.5 years of age, the patient was noted to
develop toe-walking with a tendency to trip and skip. His
ambulation has progressively worsened, but his development has otherwise been normal.
Examination showed spasticity in his lower extremities
with preserved bulk and mild weakness. Deep tendon
reflexes were brisk in both legs. He had bilateral extensor
plantar responses and unsustained ankle clonus. He had a
spastic gait with toe-walking. Sensation and coordination
were normal. Diagnostic studies included neuroimaging
at 9 years with nonspecific signal abnormalities in the
dentate nuclei consistent with edema (hypointense abnormalities on T1-weighted images and hyperintense abnormalities on T2-weighted images; Fig. 1); otherwise, serum

Figure 1. Magnetic resonance imaging of the brain (A) T2-weighted coronal and axial (B) images demonstrates abnormal signal hyperintensities
in the bilateral dentate nuclei (arrows and arrowheads, respectively) (C) T1-weighted axial images demonstrated abnormal signal hypointensities.
Together these findings are consistent with localized edema of the dentate nuclei.
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lactate, plasma amino acids (including alanine), urine
organic acids, and acylcarnitine profile were normal.
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Exome sequencing identified two novel variants. One
paternal nonsense variant, (c.646 C>T; p.Q216X) and a
maternal missense variant, (c.407 C>A; p.P136H) (Fig. 2).
Neither of these were observed in ~6500 individuals in
the NHLBI Exome Sequencing Project. The P136H variant is a nonconservative amino acid substitution at a residue that is conserved among vertebrates (Fig. 2). The
new residue differs in size, polarity, and charge. The
Q216X variant truncates mtPheRS near its midpoint,
omitting the enzymatic catalytic core and anticodon-binding domain (Fig. 2).

to the instability or protease degradation of the truncated
peptide and indicates that the truncated protein has no
residual activity as a result of this instability.
Aminoacylation activity of the WT and P136H
mtPheRS was evaluated (Fig. 3). The P136H mutant had
a 50% reduction in activity compared to the WT enzyme
(Fig. 3). This was further shown to equate to a 10-fold
decrease in the kcat/KM for P136H compared to the WT
mtPheRS (Fig. 3). A large decrease in kcat/KM indicates a
potentially physiologically significant reduction in the efficiency with which tRNAPhe can be aminoacylated by
phenylalanine. Thermostability assays were completed
with active site titrations after 1-h incubation at room
temperature and 37°C. These studies revealed that
mtPheRS-P136H’s thermal stability was similar to WT
(Fig. S1).

Biochemical evaluation

Discussion

Both the wild-type- (WT) and P136H-mtPheRS recombinant proteins were overexpressed and purified; however,
the Q216X variant was unable to be isolated despite
numerous attempts with nickel affinity and anion
exchange columns. We were unable to isolate the Q216X
protein in the context of the c.646 C>T point mutation,
nor in our attempt to specifically only express the first
216 amino acids of mtPheRS. This was presumably due

Pure spastic paraplegia consists of lower extremity spasticity and dysfunction, without other neurological or cognitive issues. Our subject possessed novel compound
heterozygous mutations in FARS2 (Q216X and P136H)
resulting in a pure spastic paraplegia syndrome that was
also associated with bilateral signal abnormalities of the
dentate nuclei. His phenotype was similar to a previously
reported consanguineous Chinese family with pure spastic

Genetic findings

Figure 2. Pedigree and FARS2 mutations. (A) Family Pedigree. The proband is indicated by an arrow and the affected individual is in black. (B)
FARS2 gene schematic and location of mutations. Our subject’s mutations (P136H and Q216X) and previously reported cases with pure spastic
paraplegia are in black. Previously reported moderate cases are in gray and above the schematic, previously reported severe cases are in gray and
below the schematic. (C) Protein homology at mutated residues across species. The P136 and Q216 residues are conserved across most vertebrate
species.
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Figure 3. Biochemical analysis of variants. (A) Crystal structure of mtPheRS. Yellow residue denotes the P136H residue. Red region denotes the
portion of mtPheRS removed in Q216X truncation. Blue region is the portion of mtPheRS present in Q216X variant15 (B) Aminoacylation curve of
generation of Phe-tRNAPhe. Blue line is WT mtPheRS and gray line is P136H mtPheRS. (C) Steady-state kinetic parameters tRNAPhe. *Individual
kinetic parameters could not be obtained due to the high KM compared to practical tRNA concentrations ([S]  [E]). Therefore, the kcat/KM was
directly estimated from V = kcat/KM([E][S]).

paraplegia due to homozygous mutations within the catalytic domain of mtPheRS (D142Y), although their neuroimaging was normal.12 To date, these subjects represent
the mildest cases of FARS2-related disease. Overall,
approximately 21 subjects with FARS2-related disease
have been reported, with most cases (12 of 21; see
Table S1) presenting with a severe phenotype consisting
of epileptic encephalopathy and diffuse cortical dysfunction (lower extremity spasticity, motor delays, and cognitive disability). Many of these severe cases were also
associated with lactic acidosis or liver disease.6–8 Several
moderate phenotypes have also been reported with diffuse
cortical dysfunction, but had more functional capabilities.10–12 Examples included two siblings with compound
heterozygous mutations (R419C & microdeletion) presenting with intellectual disability, truncal hypotonia,
appendicular hypertonicity, and neonatal epilepsy).11
Additional moderate subjects included two unrelated children with diffuse cortical dysfunction and lactic acidosis.10 One child (P361L & V174del) had additional
findings of bradykinesia and dystonia, whereas the other
(P361L & A154V) also developed epilepsy. Both had neuroimaging abnormalities in the frontopontine pyramidal
tracts, thalamus, and cerebellar atrophy.10 In contrast to
the subjects with pure spastic paraplegia, these individuals

could be classified as complex spastic paraplegia due to
their combination of spasticity and other significant neurological issues.
The variable severity of the FARS2 phenotypes may be
related to the amount of residual mtPheRS activity each
individual possesses. This residual activity may play a role
in both neuro-development, as well as the long-term
maintenance of the nervous system. Previous work
revealed mitochondrial dysfunction can disrupt migration
of cortical interneurons and lead to epileptic
encephalopathy and/or intellectual disability.13 One could
hypothesize that individuals with reduced mtPheRS activity leading to severe FARS2 phenotypes (associated with
larger energy deficits) could possess these migrational
anomalies, as well as being vulnerable to developing lateronset injury in cells with higher energy requirements
(e.g., cerebellar Purkinje or cortical pyramidal cells), leading to their complex spastic paraplegia. Alternatively,
individuals with higher residual mtPheRS activity may
generate enough energy for normal interneuron migration, resulting in their phenotype solely being a function
of later-onset injury to cells with higher energy requirements. Our subject had residual mtPheRS activity as a
result of a partially active substitution mutation (P136H)
combined with an unstable null truncation variant
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(Q216X). This may be why his phenotype is currently
limited to a pure spastic paraplegia syndrome.
Although our subject presented with the same phenotype as the consanguineous Chinese family, his neuroimaging revealed bilateral signal abnormalities of the
dentate nuclei. Of note, our subject was not the only
FARS2-related patient with changes in this location.
Similar abnormalities were also seen in a child with a
more severe clinical phenotype and additional neuroimaging features that included a thin corpus callosum,
white matter changes, and diffuse cerebral cortical atrophy.9 Interestingly, another case with a similar presentation to our subject involved SARS2, a gene encoding a
mt-aaRS for serine.14 In that report, homozygous splice
site mutations led to partial activity of the mitochondrial seryl-tRNA synthetase (mtSerRS) resulting in
spastic paraplegia and mild intellectual disability. Interestingly, this child also presented with increased T2
hyperintensities in the dentate nuclei with later development of cerebellar atrophy. Both our subject and this
child were without clinical cerebellar findings. It may be
that in both subjects’ dentate changes are not contributing to their spasticity; nevertheless, cerebellar dysfunction is frequently associated with spastic paraplegia and
in this context, may be playing a role. It could also be
that with time, both subjects develop cerebellar symptoms. The identification and long-term follow-up of
more FARS2 or other mt-aaRS patients with pure spastic paraplegia will be required to better understand these
associations.
Aminoacyl-tRNA synthetases have been associated with
a range of symptoms from early-onset mitochondrial phenotypes to milder forms with later-onset neurological
findings. The more common phenotype of FARS2 disorders is a severe disorder with epileptic encephalopathy
and severe neurological abnormalities affecting the function of deep gray nuclei and the cerebral cortex. We
report a subject presenting with pure spastic paraplegia
without familial consanguinity. This case further underscores the idea that the phenotype related to FARS2 and
other mt-aaRSs may have a wide spectrum of disease
severity. The subject reported here will require continued
monitoring to determine if his course has plateaued or
may progress; however, in the context of reported FARS2related disease, it may be that pure spastic paraplegia is
the mildest presentation.
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